Xencor, Inc.
NASDAQXencor reports today with the same bullish options skew that defined the July 29 preview still intact — but the stock has done very little since, keeping the tension between optimistic positioning and a still-heavy short base firmly unresolved. The options setup remains the loudest signal. The put/call ratio has barely moved since last week, now at 0.28 — still roughly 0.8 standard…
XNCR put-call ratio crashes to 0.37, -4 standard deviations below 20-day mean of 1.25, signaling extreme call dominance as stock surges 48.8% in one month.
Snapshot as of 7 Aug 2026
Xencor reports today with the same bullish options skew that defined the July 29 preview still intact — but the stock has done very little since, keeping the tension between optimistic positioning and a still-heavy…
Xencor enters its August 4 earnings report in an unusual position: a 33% rally over the past month has stripped out a meaningful chunk of short positioning, while options traders have swung to their most bullish…
XNCR carries one of the more stubborn short positions in small-cap biotech into Thursday's Q1 2026 report — and the lending market says the bears have plenty of capacity left to press. Short interest is running at…
Xencor reports Q1 results after the close on May 6 that land well short of expectations — EPS of -$1.71 against a -$0.75 estimate, with revenues of $4.5M versus the $27.8M the Street had modelled. The Q1 miss arrives…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for XNCR — free to start on ORTEX.
Sign up for free →Open XNCR on ORTEX